Updated:
Puma Biotechnology
Puma Biotechnology was founded in 2010 by Alan H. Auerbach, who recognized the clinical potential in neratinib, an oral pan-HER inhibitor that Pfizer had...
Puma Biotechnology
Puma Biotechnology was founded in 2010 by Alan H. Auerbach, who recognized the clinical potential in neratinib, an oral pan-HER inhibitor that Pfizer had decided not to advance. Auerbach in-licensed the molecule, took the company public in 2012, and shepherded it through pivotal clinical trials over the next five years. The company's formation represents a familiar biotech arbitrage: acquiring a deprioritized pharmaceutical asset and funding its development through public equity markets. The firm's strategy concentrates entirely on the development, regulatory approval, and commercialization of neratinib for HER2-positive cancers. The lead asset, Nerlynx, is FDA-approved for extended adjuvant treatment of early-stage HER2-positive breast cancer and, in combination with capecitabine, for later-line metastatic disease. Puma earns nearly all its revenue from U.S. sales of Nerlynx, which reached $46.5 million in net revenue for the fourth quarter of 2024, putting the annual run rate above $200 million. The company also licenses neratinib to Knight Therapeutics for Canada, to Specialised Therapeutics for Australia and Southeast Asia, and to other partners across Latin America, the Middle East, and North Africa. Puma runs a lean commercial and medical-affairs organization with approximately 137 employees as of its 2024 annual report. The firm is headquartered in Los Angeles, California. In February 2025, Auerbach initiated an unsolicited effort to take the company private through an acquisition vehicle he controls, offering an estimated $200 to $220 million to buy the shares he does not already own, valuing the enterprise above its cash position but below the peak valuations seen during the commercial ramp (per SEC filings, February 2025). The company generates enough cash from Nerlynx sales to fund ongoing clinical work on new neratinib combinations without secondary offerings. Puma Biotechnology's structural differentiator is its extreme asset concentration. Unlike larger oncology companies that diversify across mechanisms of action and tumor types, Puma is a publicly traded wrapper around a single molecule. Every strategic decision—capital allocation, regulatory filings, commercial partnerships, and the recent go-private attempt—flows from managing neratinib's life cycle. This focus makes the company's financial fate one of the purest bets in biotech on a single drug's commercial trajectory.
General information
Firm type
Asset Manager
Year founded
2010
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Los Angeles
Corporate office
10880 Wilshire Blvd, Suite 2150, Los Angeles, CA 90024, United States
Principals
Alan H. Auerbach
Chairman, Chief Executive Officer, and President
Maximo F. Nougues
Chief Financial Officer and Treasurer
Alvin F. Wong
Chief Scientific Officer
Sector focus
Frequently asked questions
What is Puma Biotechnology's lead product and what condition does it treat?
Puma's sole commercial product is Nerlynx (neratinib), an oral pan-HER tyrosine kinase inhibitor. It is approved in the United States for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer following one year of trastuzumab, and in combination with capecitabine for patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens.
Who makes the key investment and operational decisions at Puma Biotechnology?
Founder, Chairman, and CEO Alan H. Auerbach controls investment and strategic decisions through his dual role as the company's largest individual shareholder and C-suite executive. In February 2025, he proposed taking the company private, signaling an intention to concentrate operational control further. Maximo Nougues serves as CFO, and Alvin Wong is Chief Scientific Officer.
How did Puma Biotechnology acquire its primary drug asset?
Alan Auerbach secured an exclusive license to neratinib from Pfizer in 2010 after the larger pharmaceutical company deprioritized the asset during a pipeline review. Puma then financed the remaining clinical development through public equity offerings, listing on the NYSE in 2012 before gaining FDA approval in 2017.
How is Puma Biotechnology's commercial performance measured?
The company reports quarterly net revenue almost entirely from U.S. Nerlynx sales. For the fourth quarter of 2024, Puma recorded $46.5 million in net revenue. Full-year 2024 revenue was $187.5 million, with the Q4 exit rate suggesting an annualized revenue run rate above $200 million. The company also earns royalties from licensing partners in Canada, Australia, Southeast Asia, and other territories.
Is Puma Biotechnology structure more like a family office or a traditional operating company?
Puma Biotechnology is a publicly traded commercial-stage biopharmaceutical company—not a family office. The confusion often arises because founder-led, single-asset biotech companies can resemble concentrated investment vehicles. Puma has its own sales force, R&D organization, and regulatory apparatus, operating on the NASDAQ under the ticker PBYI.
Does Puma Biotechnology invest in other companies or maintain an external venture portfolio?
Puma Biotechnology does not operate an external venture-capital arm or maintain a portfolio of third-party biotech investments. Its capital is deployed internally to fund clinical trials for neratinib in additional indications, such as HR-positive breast cancer and other HER2-mutated solid tumors. It does not participate in fund commitments or operate as a limited partner.
What is the firm's known posture on geographic expansion or M&A?
Puma does not pursue an active M&A strategy. Growth comes from expanding Nerlynx into new indications and new geographies through licensing deals, not through acquiring other companies or drug candidates. The February 2025 go-private proposal suggests the CEO prefers a long-duration capital structure with fewer public-market distractions, not a roll-up strategy.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: